Panbela Therapeutics, Inc.
PBLA · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $1,726 | $1,748 | $1,719 | $4,341,382 |
| - Cash | $142 | $59 | $262 | $2,578 |
| + Debt | $6,394 | $4,194 | $4,194 | $5,194 |
| Enterprise Value | $7,978 | $5,883 | $5,651 | $4,343,998 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$7,165 | -$8,103 | -$6,726 | -$7,047 |
| % Margin | – | – | – | – |
| EBITDA | -$6,730 | -$6,057 | -$7,195 | -$6,421 |
| % Margin | – | – | – | – |
| Net Income | -$7,172 | -$7,139 | -$7,120 | -$6,474 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.48 | -1.47 | -2.28 | -0.027 |
| % Growth | -0.7% | 35.5% | -8,251.6% | – |
| Operating Cash Flow | -$2,120 | -$981 | -$9,392 | -$3,080 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$2,120 | -$981 | -$9,392 | -$3,080 |